Viyash Scientific Limited Reports 17.8% Revenue Growth and 49.4% Profit Rise for H1 FY27 with Strategic Expansion Moves
Company completes BioForLife acquisition in Italy and advances investments in oncology and manufacturing capacities
Viyash Scientific Limited announced a 17.8% increase in revenue to ₹19,343 million and a 49.4% rise in profit after tax to ₹1,639 million for the half year ended September 30, 2026. The company also completed the acquisition of BioForLife in Italy and is investing in oncology capabilities and capacity expansion.
Viyash Scientific Limited
General / Other
Viyash Scientific Limited posted a 17.8% increase in revenue to ₹19,343 million and a 49.4% rise in profit after tax to ₹1,639 million for the half year ended September 30, 2026, reflecting growth across its integrated pharmaceutical operations.
The company’s EBITDA before ESOP costs rose 29.9% to ₹4,124 million, with a margin of 21.3% for H1 FY27. Its Q2 revenue alone reached ₹9,879 million, up 16.2% year-over-year, while EBITDA grew 10.3% to ₹2,077 million.
Viyash Scientific completed the acquisition of BioForLife in Italy, enhancing its position in the companion animal health segment. Additionally, the company is investing in new oncology capabilities, an in-house facility for companion animal manufacturing, and expanding its API production capacity to meet increasing customer demand.
The company reported a net debt to EBITDA ratio of 0.0x for the quarter, down from 0.7x the previous year, indicating improved debt management.
An earnings call to discuss the results and company outlook was scheduled for November 14, 2026.
Highlights
- H1 FY27 revenue of ₹19,343 million, up 17.8% year-over-year
- Profit after tax for H1 FY27 reached ₹1,639 million, up 49.4%
- Q2 FY27 revenue at ₹9,879 million with a 16.2% year-over-year increase
- EBITDA before ESOP costs for H1 FY27 at ₹4,124 million, representing a 29.9% increase
- Completed acquisition of BioForLife in Italy to strengthen companion animal platform
- Investments underway in oncology capabilities and manufacturing expansion for companion animal products
Key Data Snapshot
What happened
- Viyash Scientific Limited reported financial results for the quarter and half year ended September 30, 2026.
- Revenue for H1 FY27 increased by 17.8% to ₹19,343 million compared to H1 FY26.
- Profit after tax for H1 FY27 rose 49.4% to ₹1,639 million year-over-year.
- EBITDA before ESOP costs for H1 FY27 improved 29.9% to ₹4,124 million.
- Net debt to EBITDA ratio improved to 0.0x from 0.7x a year ago.
Key details
- Q2 FY27 revenue stood at ₹9,879 million, up 16.2% year-over-year, with EBITDA of ₹2,077 million at a 21.0% margin.
- Adjusted PAT for Q2 FY27 with normalized ESOP cost is ₹1,110 million.
- The acquisition of BioForLife in Italy was completed, strengthening the company's companion animal platform.
- Viyash Scientific is investing in oncology capabilities, an in-house companion animal manufacturing facility, and expanding its active pharmaceutical ingredient (API) capacity to meet demand.
Background and context
- Viyash Scientific Limited is an integrated pharmaceutical company with products and services serving human and animal health segments.
- The company operates 16 manufacturing facilities with regulatory approvals from USFDA, EU GMP, WHO, and TGA.
- It has a global presence with operations across India, Spain, Brazil, Turkey, and the USA.
- Viyash is among the top-25 global animal health companies with a diverse portfolio including 110+ APIs, 30+ human health, and 140+ animal health formulations.
Next milestones
- Earnings call scheduled for November 14, 2026, at 11:00 AM IST to discuss financial results and take investor questions.
- The company will focus on execution of investments in oncology and companion animal manufacturing capabilities and API capacity expansion.
Highlights
- H1 FY27 revenue of ₹19,343 million, up 17.8% year-over-year
- Profit after tax for H1 FY27 reached ₹1,639 million, up 49.4%
- Q2 FY27 revenue at ₹9,879 million with a 16.2% year-over-year increase
- EBITDA before ESOP costs for H1 FY27 at ₹4,124 million, representing a 29.9% increase
- Completed acquisition of BioForLife in Italy to strengthen companion animal platform
- Investments underway in oncology capabilities and manufacturing expansion for companion animal products
Disclosures
- Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
More News on General / Other
View allLatest corporate announcements and market updates in General / Other.
Sobhagya Mercantile Ltd. Sets Extraordinary General Meeting for December 11, 2026, via Video Conferencing
Sobhagya Mercantile Limited has issued a public notice convening an Extraordinary General Meeting (EGM) scheduled for December 11, 2026, at 11:30 A.M. IST. The meeting will be conducted through video conferencing and other audio-visual means, with e-voting facilities provided to shareholders.
Read Full StoryAPL Apollo Tubes Denies Promoter Stake Sale Rumors Following Speculative News
APL Apollo Tubes Limited issued a clarification on November 20, 2026, denying any knowledge or communication regarding a proposed sale of promoter family shares amid speculative media reports.
Read Full StoryIndusInd Bank Conducts November 2026 Investor and Analyst Meetings in Chennai with Leading Asset Managers
On November 19, 2026, IndusInd Bank Limited conducted analyst and institutional investor meetings in Chennai, involving prominent asset management companies such as Franklin Templeton, Bandhan AMC, Axis AMC, and Motilal Oswal AMC. The bank clarified no unpublished price sensitive information was shared during these discussions.
Read Full Story